论文部分内容阅读
目的观察曲妥珠单抗联合长春瑞滨方案治疗人表皮生长因子受体2(HER-2)阳性晚期乳腺癌的疗效及安全性。方法收集中国医学科学院肿瘤医院2001年2月至2012年2月期间应用曲妥珠单抗联合含长春瑞滨化疗方案治疗的55例晚期乳腺癌患者的临床资料。回顾性分析其临床特点、药物疗效、不良反应及生存状况。结果应用曲妥珠单抗联合含长春瑞滨方案治疗的55例患者中,完全缓解(CR)2例,部分缓解(PR)24例,疾病稳定(SD)16例,疾病进展(PD)13例,总有效率为47.3%,疾病控制率为76.4%,中位PFS为8.0个月。患者中位生存时间为46.1个月,1年生存率为95.8%,2年生存率为76.8%,5年生存率为45.7%。3例心悸考虑为曲妥珠单抗相关的不良反应,患者未出现明显心功能不全。不良反应主要为化疗药物导致的血液学毒性和非血液学毒性。结论曲妥珠单抗联合含长春瑞滨方案治疗HER-2阳性的晚期乳腺癌疗效肯定,毒性可耐受。
Objective To observe the efficacy and safety of trastuzumab plus vinorelbine regimen in the treatment of human epidermal growth factor receptor 2 (HER-2) positive advanced breast cancer. Methods The clinical data of 55 patients with advanced breast cancer treated with trastuzumab combined with vinorelbine chemotherapy from February 2001 to February 2012 in Cancer Hospital of Chinese Academy of Medical Sciences were collected. Retrospective analysis of its clinical features, drug efficacy, adverse reactions and survival status. Results Among the 55 patients treated with trastuzumab plus vinorelbine, there were 2 cases of complete remission (CR), 24 cases of partial remission (PR), 16 cases of stable disease (SD), 13 cases of disease progression (PD) For example, the total effective rate was 47.3%, the disease control rate was 76.4%, and the median PFS was 8.0 months. The median survival time was 46.1 months. The 1-year survival rate was 95.8%, the 2-year survival rate was 76.8%, and the 5-year survival rate was 45.7%. Three cases of palpitations were considered trastuzumab-related adverse reactions, and patients did not have significant cardiac insufficiency. Adverse reactions are mainly hematologic and nonhematological toxicities caused by chemotherapy drugs. Conclusion Trastuzumab combined with vinorelbine regimen for the treatment of HER-2-positive advanced breast cancer is effective and tolerable.